Search

Your search keyword '"Lewis, Andrew L."' showing total 654 results
Start Over Author "Lewis, Andrew L."
654 results on '"Lewis, Andrew L."'

151. Feasibility of Intracoronary GLP-1 Eluting CellBead™ Infusion in Acute Myocardial Infarction

Author

Houtgraaf, Jaco H., primary, De Jong, Renate, additional, Monkhorst, Kim, additional, Tempel, Dennie, additional, Van De Kamp, Esther, additional, Den Dekker, Wijnand K., additional, Kazemi, Kushan, additional, Hoefer, Imo, additional, Pasterkamp, Gerard, additional, Lewis, Andrew L., additional, Stratford, Peter W., additional, Wallrapp, Christine, additional, Zijlstra, Felix, additional, and Duckers, Henricus J., additional

Published
2013
Full Text
View/download PDF

154. Benefits of polidocanol endovenous microfoam (Varithena®) compared with physician-compounded foams.

Author

Carugo, Dario, Ankrett, Dyan N., Zhao, Xuefeng, Zhang, Xunli, Hill, Martyn, O’Byrne, Vincent, Hoad, James, Arif, Mehreen, Wright, David D. I., and Lewis, Andrew L.

Subjects
BIOTECHNOLOGY, CARBON dioxide, PHYSICAL & theoretical chemistry, DRUG stability, DOSAGE forms of drugs, SCLEROTHERAPY, OXYGEN, PROBABILITY theory, SAPHENOUS vein, VARICOSE veins, WEIGHTS & measures, DESCRIPTIVE statistics, DRUG administration, DRUG dosage
Abstract

Objective To compare foam bubble size and bubble size distribution, stability, and degradation rate of commercially available polidocanol endovenous microfoam (Varithena®) and physician-compounded foams using a number of laboratory tests. Methods Foam properties of polidocanol endovenous microfoam and physician-compounded foams were measured and compared using a glass-plate method and a Sympatec QICPIC image analysis method to measure bubble size and bubble size distribution, Turbiscan™ LAB for foam half time and drainage and a novel biomimetic vein model to measure foam stability. Physician-compounded foams composed of polidocanol and room air, CO2, or mixtures of oxygen and carbon dioxide (O2:CO2) were generated by different methods. Results Polidocanol endovenous microfoam was found to have a narrow bubble size distribution with no large (>500 µm) bubbles. Physician-compounded foams made with the Tessari method had broader bubble size distribution and large bubbles, which have an impact on foam stability. Polidocanol endovenous microfoam had a lower degradation rate than any physician-compounded foams, including foams made using room air (p < 0.035). The same result was obtained at different liquid to gas ratios (1:4 and 1:7) for physician-compounded foams. In all tests performed, CO2 foams were the least stable and different O2:CO2 mixtures had intermediate performance. In the biomimetic vein model, polidocanol endovenous microfoam had the slowest degradation rate and longest calculated dwell time, which represents the length of time the foam is in contact with the vein, almost twice that of physician-compounded foams using room air and eight times better than physician-compounded foams prepared using equivalent gas mixes. Conclusion Bubble size, bubble size distribution and stability of various sclerosing foam formulations show that polidocanol endovenous microfoam results in better overall performance compared with physician-compounded foams. Polidocanol endovenous microfoam offers better stability and cohesive properties in a biomimetic vein model compared to physician-compounded foams. Polidocanol endovenous microfoam, which is indicated in the United States for treatment of great saphenous vein system incompetence, provides clinicians with a consistent product with enhanced handling properties. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

155. DC BeadM1TM: towards an optimal transcatheter hepatic tumour therapy.

Author

Lewis, Andrew L., Dreher, Matthew R., O’Byrne, Vincent, Grey, David, Caine, Marcus, Dunn, Anthony, Yiqing Tang, Hall, Brenda, Fowers, Kirk D., Johnson, Carmen Gacchina, Sharma, Karun V., and Wood, Bradford J.

Abstract

Clinical use of DC BeadTM loaded with doxorubicin (DEBDOXTM) or irinotecan (DEBIRITM), for the treatment of primary and secondary tumours of the liver respectively, is showing great promise. Recently there has been a tendency to select smaller bead size ranges to treat tumours in an effort to allow more drug dose to be administered, improve tumoural penetration and resultant drug delivery and tumour coverage. Herein we describe the development and performance characterisation of a new DC Bead size range (DC BeadM1TM, 70–150 lm) capable of an increased bead delivery in the distal vasculature, corresponding to greater tumour coverage and drug dose delivered. Both unloaded and drug loaded DC BeadM1 were shown to have a greater density of distal volume of penetration although the ultimate distal level of penetration was the same as that of the 100–300 lm beads in an in vitro penetration model. Elution of doxorubicin was slower than irinotecan elution, but it was similar when comparing the same drug elution from 70 to 150 lm compared to 100–300 lm beads. Radiopaque versions of 70–150 and 100–300 lm beads were prepared in order to evaluate distribution ex vivo using l-CT and doxorubicin distribution using epifluorescent microscopy. Liver distribution of the radiopaque versions of the beads was shown to be more distal and efficient at filling smaller vessels with the DC BeadM1 and correspondingly more beads were found per vessel histologically with a larger area of drug coverage with the smaller size range. This study indicates that the smaller (70–150 lm) beads should permit an increased dose of drug to be administered to both hypervascular and hypovascular tumours as compared to 100–300 lm beads. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

162. Development of a combination drug-eluting bead

Author

Forster, Richard E.J., primary, Tang, Yiqing, additional, Bowyer, Cressida, additional, Lloyd, Andrew W., additional, Macfarlane, Wendy, additional, Phillips, Gary J., additional, and Lewis, Andrew L., additional

Published
2012
Full Text
View/download PDF

163. Radiopaque Drug-Eluting Beads for Transcatheter Embolotherapy: Experimental Study of Drug Penetration and Coverage in Swine

Author

Dreher, Matthew R., primary, Sharma, Karun V., additional, Woods, David L., additional, Reddy, Goutham, additional, Tang, Yiqing, additional, Pritchard, William F., additional, Chiesa, Oscar A., additional, Karanian, John W., additional, Esparza, Juan A., additional, Donahue, Danielle, additional, Levy, Elliot B., additional, Willis, Sean L., additional, Lewis, Andrew L., additional, and Wood, Bradford J., additional

Published
2012
Full Text
View/download PDF

171. Controlling Polymersome Surface Topology at the Nanoscale by Membrane Confined Polymer/Polymer Phase Separation

Author

LoPresti, Caterina, primary, Massignani, Marzia, additional, Fernyhough, Christine, additional, Blanazs, Adam, additional, Ryan, Anthony J., additional, Madsen, Jeppe, additional, Warren, Nicholas J., additional, Armes, Steven P., additional, Lewis, Andrew L., additional, Chirasatitsin, Somyot, additional, Engler, Adam J, additional, and Battaglia, Giuseppe, additional

Published
2011
Full Text
View/download PDF

179. Development of “Imageable” Beads for Transcatheter Embolotherapy

Author

Sharma, Karun V., primary, Dreher, Matthew R., additional, Tang, Yiqing, additional, Pritchard, William, additional, Chiesa, Oscar A., additional, Karanian, John, additional, Peregoy, Jennifer, additional, Orandi, Babak, additional, Woods, David, additional, Donahue, Danielle, additional, Esparza, Juan, additional, Jones, Guy, additional, Willis, Sean L., additional, Lewis, Andrew L., additional, and Wood, Bradford J., additional

Published
2010
Full Text
View/download PDF

196. Non-cytotoxic polymer vesicles for rapid and efficient intracellular delivery

Author

Lomas, Hannah, primary, Massignani, Marzia, additional, Abdullah, Khairuddin A., additional, Canton, Irene, additional, Lo Presti, Caterina, additional, MacNeil, Sheila, additional, Du, Jianzhong, additional, Blanazs, Adam, additional, Madsen, Jeppe, additional, Armes, Steven P., additional, Lewis, Andrew L., additional, and Battaglia, Giuseppe, additional

Published
2008
Full Text
View/download PDF

200. Direct Quantification and Comparison of Intratumoral Hypoxia following Transcatheter Arterial Embolization of VX2 Liver Tumors with Different Diameter Microspheres.

Author

Levy, Elliot B., Gacchina Johnson, Carmen, Jacobs, Genevieve, Woods, David L., Sharma, Karun V., Bacher, John D., Lewis, Andrew L., Dreher, Matthew R., and Wood, Bradford J.

Abstract

Purpose: To evaluate the effect of embolic diameter on achievement of hypoxia after embolization in an animal model of liver tumors.Materials and Methods: Inoculation of VX2 tumors in the left liver lobe was performed successfully in 12 New Zealand white rabbits weighing 3.7 kg ± 0.5 (mean ± SD). Tumors were deemed eligible for oxygen measurements when the maximum transverse diameter measured 15 mm or more by ultrasound examination. Direct monitoring of oxygenation of implanted rabbit hepatic VX2 tumors was performed with a fiberoptic electrode during and after transarterial embolization of the proper hepatic artery to angiographic flow stasis with microspheres measuring 70-150 μm, 100-300 μm, or 300-500 μm in diameter.Results: Failure to achieve tumor hypoxia as defined despite angiographic flow stasis was observed in 10 of 11 animals. Embolization microsphere size effect failed to demonstrate a significant trend on hypoxia outcome among the diameters tested, and pair-wise comparisons of different embolic diameter treatment groups showed no difference in hypoxia outcome. All microsphere diameters tested resulted in similar absolute reduction (24.3 mm Hg ± 18.3, 29.1 mm Hg ± 1.8, and 19.9 mm Hg ± 9.3, P = .66) and percentage decrease in oxygen (56.0 mm Hg ± 23.9, 56.0 mm Hg ± 6.4, and 35.8 mm Hg ± 20.6, P = .65). Pair-wise comparisons for percent tumor area occupied by embolic agents showed a significantly reduced fraction for 300-500 μm diameters compared with 70-150 μm diameters (P < .05).Conclusions: In the rabbit VX2 liver tumor model, three tested microsphere diameters failed to cause tumor hypoxia as measured by a fiberoptic probe sensor according to the adopted hypoxia definitions. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results